Patients suffering from Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) don’t want to wait for relief. LINZESS is a once-daily treatment that can allow patients to proactively manage their symptoms.1
IBS-C Trials 1 and 2: time to maximum CSBM frequency and abdominal pain with LINZESS treatment1
In clinical trials, patients experienced reduced abdominal pain and more frequent CSBMs over the 12-week treatment period. During the 4-week randomized withdrawal period of Trial 1, LINZESS-treated patients re-randomized to placebo experienced a return in abdominal pain severity toward baseline within 1 week.1
IBS-C Trial 1: change in abdominal pain observed during the 4-week randomized withdrawal (RW) period1,21
LINZESS-treated patients re-randomized to placebo experienced a decrease of CSBM frequency toward baseline within 1 week, while patients who continued on LINZESS maintained their response for the additional 4 weeks of the study.1
IBS-C Trial 1: change in CSBM frequency observed during the 4-week randomized withdrawal (RW) period1,21
As this study shows, LINZESS is a treatment that patients with IBS-C can use to help them proactively manage their symptoms.1 LINZESS is the #1 prescribed brand by healthcare professionals for adults with IBS-C and CIC.1,19
LINZESS is the #1 prescribed brand by healthcare professionals for adults with IBS-C and CIC.1,19